Emlorákos betegek kezelése fulvesztranttal -lehetne hatékonyabb?

Translated title of the contribution: Treating breast cancer patients with fulvestrant - Could it be more efficacious?

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Fulvestrant, as an estrogen-receptor antagonist, effectively decreases the estrogen effect, which is a key factor in the development, growth and progression of the breast cancer. Its clinical advantage can appear even after several lines of unsuccessful chemo- or hormonal therapy. In our invasive ductal carcinoma cases, the clinical benefit was obvious over 40%. According to recent data using a higher dose better results can be obtained. The same is expected if the drug would be applied at an earlier stage of the disease.

Original languageHungarian
Pages (from-to)733-736
Number of pages4
JournalLege Artis Medicinae
Volume20
Issue number11
Publication statusPublished - Nov 2010

Fingerprint

Ductal Carcinoma
Growth and Development
Estrogens
Breast Neoplasms
Pharmaceutical Preparations
Therapeutics
Estrogen Receptor Antagonists
fulvestrant

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Emlorákos betegek kezelése fulvesztranttal -lehetne hatékonyabb? / Nagy, Z.

In: Lege Artis Medicinae, Vol. 20, No. 11, 11.2010, p. 733-736.

Research output: Contribution to journalArticle

@article{1f9139cbebbf4505ac8d7bf453a75f7d,
title = "Emlor{\'a}kos betegek kezel{\'e}se fulvesztranttal -lehetne hat{\'e}konyabb?",
abstract = "Fulvestrant, as an estrogen-receptor antagonist, effectively decreases the estrogen effect, which is a key factor in the development, growth and progression of the breast cancer. Its clinical advantage can appear even after several lines of unsuccessful chemo- or hormonal therapy. In our invasive ductal carcinoma cases, the clinical benefit was obvious over 40{\%}. According to recent data using a higher dose better results can be obtained. The same is expected if the drug would be applied at an earlier stage of the disease.",
keywords = "Breast cancer, Fulvestrant, Hormonal treatment",
author = "Z. Nagy",
year = "2010",
month = "11",
language = "Hungarian",
volume = "20",
pages = "733--736",
journal = "Lege Artis Medicinae",
issn = "0866-4811",
publisher = "Literatura Medica Publishing House",
number = "11",

}

TY - JOUR

T1 - Emlorákos betegek kezelése fulvesztranttal -lehetne hatékonyabb?

AU - Nagy, Z.

PY - 2010/11

Y1 - 2010/11

N2 - Fulvestrant, as an estrogen-receptor antagonist, effectively decreases the estrogen effect, which is a key factor in the development, growth and progression of the breast cancer. Its clinical advantage can appear even after several lines of unsuccessful chemo- or hormonal therapy. In our invasive ductal carcinoma cases, the clinical benefit was obvious over 40%. According to recent data using a higher dose better results can be obtained. The same is expected if the drug would be applied at an earlier stage of the disease.

AB - Fulvestrant, as an estrogen-receptor antagonist, effectively decreases the estrogen effect, which is a key factor in the development, growth and progression of the breast cancer. Its clinical advantage can appear even after several lines of unsuccessful chemo- or hormonal therapy. In our invasive ductal carcinoma cases, the clinical benefit was obvious over 40%. According to recent data using a higher dose better results can be obtained. The same is expected if the drug would be applied at an earlier stage of the disease.

KW - Breast cancer

KW - Fulvestrant

KW - Hormonal treatment

UR - http://www.scopus.com/inward/record.url?scp=78650252024&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650252024&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:78650252024

VL - 20

SP - 733

EP - 736

JO - Lege Artis Medicinae

JF - Lege Artis Medicinae

SN - 0866-4811

IS - 11

ER -